About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 131 record(s)
Req # A-2020-001551
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-116013-691, Industry Proposal for Food Advertising Restrictions to Children.Organization: Health Canada
August 2021
Req # A-2020-001557
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-115190-850.Organization: Health Canada
August 2021
Req # A-2020-001572
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-114758-959.Organization: Health Canada
August 2021
Req # A-2020-001623
Adverse Reaction Reports (AERs). Report numbers: E2B_03083944, E2B_03036508, E2B_03095782, E2B_03080779, E2B_03010213, E2B_03147692, E2B_03157562, E2B_03159820, E2B_03167805, E2B_03122964, E2B_03157322, E2B_03129600, E2B_03115530, E2B_03184491, E2B_03186766, E2B_03197158, E2B_03201957, E2B_03204648, E2B_03165795, E2B_03168878.Organization: Health Canada
August 2021
Req # A-2020-001654
Adverse Reaction Reports (AERs) for HYDROXYCHLOROQUINE SULFATE. Report numbers: E2B_03234391, E2B_03236758, E2B_03239225, E2B_03237453, E2B_03181593, E2B_03174692, E2B_03185217, E2B_03195859, E2B_03198184, E2B_03198213, E2B_03203765, E2B_03213464, E2B_03217175, 000914409, 000916772.Organization: Health Canada
August 2021
Req # A-2020-001684
Adverse Reaction Reports (AERs). Report numbers: E2B_03328385, E2B_03324177, E2B_03334199, E2B_03336242, E2B_03338547, E2B_03380196, E2B_03346017, E2B_03359258, E2B_03359390, E2B_03358309, E2B_03358225, E2B_03362678, E2B_03361390, E2B_03361287, E2B_03374239, E2B_03390900, E2B_03377347, E2B_03405198, E2B_03395924, E2B_03405205.Organization: Health Canada
August 2021
Req # A-2020-001701
Adverse Reaction Reports (AERs) for Isentress. Report numbers: E2B_01366855, E2B_00089569, 000331542, 000331792, 000331998, 000643966, E2B_00499580, E2B_00702948, E2B_00719289, E2B_01304958.Organization: Health Canada
August 2021
Req # A-2020-001890
Adverse Reaction Reports (AERs) for Ondansetron. Report numbers: 925161, E2B_03393048, E2B_03381864, 925332,925195, E2B_03389645, E2B_03352312, E2B_03379452, E2B_03344059, E2B_03352501. (ADRs) for Pantoloc. Report numbers: E2B_03395569, 922680, E2B_03381450.Organization: Health Canada
August 2021
Req # A-2020-001893
Adverse Reaction Reports (AERs) for Mesalazine. Report numbers: E2B_03359485, 924994, 926580, E2B_03337925, E2B_03342971, E2B_03403768. (ADRs) for C1 Esterase Inhibitor (Human). Report numbers: E2B_03394037, E2B_03350562. (ADR) for GAMMAGARD LIQUID. Report number: 921422. (ADRs) for Immunoglobulin (human). Report numbers: E2B_03394199, E2B_03353109, E2B_03393837.Organization: Health Canada
August 2021
Req # A-2020-001894
Adverse Reaction Reports (AERs) for Ondansetron. Report numbers: E2B_03280809, E2B_03289700, E2B_03322101. (ADRs) for Pantoloc. Report numbers: E2B_03306917, 920093. (ADRs) for Pantoprazole Sodium. Report numbers: E2B_03283751, E2B_03293332, E2B_03301666. (ADRs) for Pantoprazole Magnesium. Report numbers: E2B_03330338, E2B_03323855. (ADR) for Alunbrig. Report number: E2B_03309858. (ADR) for Guanfacine (guanfacine hydrochloride). Report number: E2B_03302980.Organization: Health Canada
August 2021